
    
      This was a multicenter study evaluating the efficacy and safety of ombitasvir/
      paritaprevir/ritonavir and dasabuvir administered for 12 weeks in HCV genotype 1b
      (GT1b)-infected, treatment-na√Øve and previous pegylated interferon (pegIFN)/ ribavirin (RBV)
      treatment-experienced adults with compensated cirrhosis. The duration of the study was up to
      36 weeks (not including a screening period of up to 42 days) and consisted of a 12-week
      Treatment Period and a 24-week Post-Treatment Period for all participants who received study
      drugs.
    
  